Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Method for detection of picornavirus capsid binders with soluble intercellular adhesion molecule 1.

Last-Barney K, Marlin SD, Pal K, Cahill-Feehan C, McNally EJ, Jeanfavre DD, Merluzzi VJ.

Antimicrob Agents Chemother. 1993 Aug;37(8):1693-5.

2.
3.

Monoclonal antibody to MALA-2 (ICAM-1) reduces acute autoimmune nephritis in kdkd mice.

Harning R, Pelletier J, Van G, Takei F, Merluzzi VJ.

Clin Immunol Immunopathol. 1992 Aug;64(2):129-34.

PMID:
1353711
4.

In vitro studies of the antirhinovirus activity of soluble intercellular adhesion molecule-1.

Arruda E, Crump CE, Marlin SD, Merluzzi VJ, Hayden FG.

Antimicrob Agents Chemother. 1992 Jun;36(6):1186-91.

5.

Nonnucleoside inhibitors of HIV-1 reverse transcriptase: nevirapine as a prototype drug.

Grob PM, Wu JC, Cohen KA, Ingraham RH, Shih CK, Hargrave KD, McTague TL, Merluzzi VJ.

AIDS Res Hum Retroviruses. 1992 Feb;8(2):145-52. Review.

PMID:
1371691
6.

A novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase.

Merluzzi VJ, Rosenthal AS.

Adv Exp Med Biol. 1992;312:89-94. Review. No abstract available.

PMID:
1381140
7.

Inhibition of HIV-1 reverse transcriptase and virus replication by a non-nucleoside dipyridodiazepinone BI-RG-587 (Nevirapine).

Skoog MT, Hargrave KD, Miglietta JJ, Kopp EB, Merluzzi VJ.

Med Res Rev. 1992 Jan;12(1):27-40. Review. No abstract available.

PMID:
1371177
8.

Detection of major group rhinoviruses by soluble intercellular adhesion molecule-1 (sICAM-1).

Last-Barney K, Marlin SD, McNally EJ, Cahill C, Jeanfavre D, Faanes RB, Merluzzi VJ.

J Virol Methods. 1991 Dec;35(3):255-64.

PMID:
1687741
10.

Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma.

Harning R, Mainolfi E, Bystryn JC, Henn M, Merluzzi VJ, Rothlein R.

Cancer Res. 1991 Sep 15;51(18):5003-5.

11.

Distribution of ICAM-1 within decidua and placenta and its gestational age-associated changes.

Salafia CM, Haynes N, Merluzzi VJ, Rothlein R.

Pediatr Pathol. 1991 May-Jun;11(3):381-8.

PMID:
1714074
12.

Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587.

Koup RA, Merluzzi VJ, Hargrave KD, Adams J, Grozinger K, Eckner RJ, Sullivan JL.

J Infect Dis. 1991 May;163(5):966-70.

PMID:
1708400
13.

BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine.

Richman D, Rosenthal AS, Skoog M, Eckner RJ, Chou TC, Sabo JP, Merluzzi VJ.

Antimicrob Agents Chemother. 1991 Feb;35(2):305-8.

14.

Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor.

Merluzzi VJ, Hargrave KD, Labadia M, Grozinger K, Skoog M, Wu JC, Shih CK, Eckner K, Hattox S, Adams J, et al.

Science. 1990 Dec 7;250(4986):1411-3. Erratum in: Science 1991 Jan 25;251(4992):362.

PMID:
1701568
15.

A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection.

Marlin SD, Staunton DE, Springer TA, Stratowa C, Sommergruber W, Merluzzi VJ.

Nature. 1990 Mar 1;344(6261):70-2.

PMID:
1968231
16.

Evaluation of zinc complexes on the replication of rhinovirus 2 in vitro.

Merluzzi VJ, Cipriano D, McNeil D, Fuchs V, Supeau C, Rosenthal AS, Skiles JW.

Res Commun Chem Pathol Pharmacol. 1989 Dec;66(3):425-40.

PMID:
2558406
17.
18.

A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinoviruses.

Staunton DE, Merluzzi VJ, Rothlein R, Barton R, Marlin SD, Springer TA.

Cell. 1989 Mar 10;56(5):849-53.

PMID:
2538244
19.

Hybridoma-derived human suppressor factors: differential effects on mouse lymphocytes.

Telerman A, Merluzzi VJ, Calvelli TA, Kunicka JE, Platsoucas CD.

Hybridoma. 1989 Feb;8(1):25-36.

PMID:
2784404
20.

Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.

Kolitz JE, Wong GY, Welte K, Merluzzi VJ, Engert A, Bialas T, Polivka A, Bradley EC, Konrad M, Gnecco C, et al.

J Biol Response Mod. 1988 Oct;7(5):457-72.

PMID:
3263471
21.

A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma.

Chapman PB, Kolitz JE, Hakes TB, Gabrilove JL, Welte K, Merluzzi VJ, Engert A, Bradley EC, Konrad M, Mertelsmann R.

Invest New Drugs. 1988 Sep;6(3):179-88.

PMID:
3263958
22.
23.

Synergistic and overlapping activities of tumor necrosis factor-alpha and IL-1.

Last-Barney K, Homon CA, Faanes RB, Merluzzi VJ.

J Immunol. 1988 Jul 15;141(2):527-30.

PMID:
3260255
24.
25.

Expansion of activated T-lymphocytes in patients treated with recombinant interleukin 2.

Kolitz JE, Welte K, Wong GY, Holloway K, Merluzzi VJ, Engert A, Bradley EC, Konrad M, Polivka A, Gabrilove JL, et al.

J Biol Response Mod. 1987 Aug;6(4):412-29.

PMID:
3498011
26.

Membrane-associated interleukin 1 activity on human U937 tumor cells: stimulation of PGE2 production by human chondrosarcoma cells.

Merluzzi VJ, Faanes RB, Czajkowski M, Last-Barney K, Harrison PC, Kahn J, Rothlein R.

J Immunol. 1987 Jul 1;139(1):166-8.

PMID:
3495597
28.

Epidermal growth factor receptor is increased in multidrug-resistant Chinese hamster and mouse tumor cells.

Meyers MB, Merluzzi VJ, Spengler BA, Biedler JL.

Proc Natl Acad Sci U S A. 1986 Aug;83(15):5521-5.

29.

Similarities and distinctions between murine natural killer cells and lymphokine-activated killer cells.

Merluzzi VJ, Smith MD, Last-Barney K.

Cell Immunol. 1986 Jul;100(2):563-9.

PMID:
3489533
30.
31.

Lymphokine-activated killer cells are generated before classical cytotoxic T lymphocytes after bone marrow transplantation in mice.

Merluzzi VJ, Savage DM, Smith MD, Last-Barney K, Mertelsmann R, Moore MA, Welte K.

J Immunol. 1985 Sep;135(3):1702-6.

PMID:
3894518
32.

Production and response to interleukin 2 in vitro and in vivo after bone marrow transplantation in mice.

Merluzzi VJ, Welte K, Last-Barney K, Mertelsmann R, Souza L, Boone T, Savage DM, Quinn D, O'Reilly RJ.

J Immunol. 1985 Apr;134(4):2426-30.

PMID:
3919093
33.
34.

Lysis of spontaneous murine breast tumors by human interleukin 2-stimulated syngeneic T-lymphocytes.

Merluzzi VJ, Savage DM, Souza L, Boone T, Mertelsmann R, Welte K, Last-Barney K.

Cancer Res. 1985 Jan;45(1):203-6.

35.

Expansion of murine cytotoxic precursors in vitro and in vivo by purified interleukin-2.

Merluzzi VJ, Last-Barney K.

J Biol Response Mod. 1984 Oct;3(5):468-74.

PMID:
6334134
36.

Rescue of anti-influenza A virus cytotoxic T-lymphocyte responses in chemotherapy-suppressed mice.

Merluzzi VJ, Welte K, Mertelsmann RH, Souza L, Boone T, Last-Barney K.

J Virol. 1984 Jul;51(1):20-5.

37.

Generation of nonspecific murine cytotoxic T cells in vitro by purified human interleukin 2.

Merluzzi VJ, Savage DM, Mertelsmann R, Welte K.

Cell Immunol. 1984 Mar;84(1):74-84.

PMID:
6199125
38.

Expansion of cyclophosphamide-resistant cytotoxic precursors in vitro and in vivo by purified human interleukin 2.

Merluzzi VJ, Welte K, Savage DM, Last-Barney K, Mertelsmann R.

J Immunol. 1983 Aug;131(2):806-9.

PMID:
6134774
39.
40.
41.

Human interleukin 2: physiology, biochemistry, and pathophysiology in lymphoblastic leukemias and immunodeficiency syndromes.

Welte K, Venuta S, Wang CY, Feldman SP, Ciobanu N, Kruger G, Feickert HJ, Merluzzi VJ, Flomenberg N, Moore MA, Mertelsmann R.

Haematol Blood Transfus. 1983;28:369-79. No abstract available.

PMID:
6602744
42.

Recovery of humoral and cellular immunity by soluble mediators after 5-fluorouracil-induced immunosuppression.

Merluzzi VJ, Last-Barney K, Susskind BM, Faanes RB.

Clin Exp Immunol. 1982 Nov;50(2):318-26.

43.

Anomalous killer cells: thymus cell dependency, precursor frequency, and response to immunosuppressive therapy.

Merluzzi VJ, Kenney RE, Last-Barney K, O'Reilly RJ, Faanes RB.

Clin Immunol Immunopathol. 1982 Jul;24(1):83-92. No abstract available.

PMID:
7049474
44.

Effect of cytarabine on cytotoxic T-cell development.

Merluzzi VJ, Susskind BM, Faanes RB.

Cancer Treat Rep. 1982 Mar;66(3):535-40. No abstract available.

PMID:
6800655
45.

Immunoenhancing activity of NPT 15392: a potential immune response modifier.

Merluzzi VJ, Walker MM, Williams N, Susskind B, Hadden JW, Faanes RB.

Int J Immunopharmacol. 1982;4(3):219-24.

PMID:
7049973
46.
48.
49.
50.

Supplemental Content

Loading ...
Support Center